ABC | Volume 113, Nº5, November 2019

Original Article Congo et al. New-Onset atrial fibrillation in STEMI Arq Bras Cardiol. 2019; 113(5):948-957 1. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic reviewof the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038-45. 2. Gorenek B, Kudaiberdieva G. Atrial fibrillation in acute ST-elevation myocardial infarction: clinical and prognostic features. Curr Cardiol Rev. 2012;8(4):281-9. 3. Walkey AJ, HogarthDK, LipGYH. Optimizing atrial fibrillationmanagement: from ICU and beyond. Chest. 2015;148(4):859-64. 4. Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care. 2014;18(6):688. 5. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011;123(15):1587-93. 6. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94(7):867-73. 7. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, et al. An open-label,randomized,controlled,multicenterstudyexploringtwotreatment strategiesofrivaroxabanandadose-adjustedoralvitaminKantagonisttreatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). AmHeart J. 2015;169(4):472-8. 8. Alasady M, Abhayaratna WP, Leong DP, Lim HS, Abed HS, Brooks AG, et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8(7):955-60. 9. Goldberg R, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: acommunity-wide perspective. Am Heart J. 2002;143(3):519-27. 10. Rubenstein J, Cinquegrani MP, Wright J. Atrial fibrillation in acute coronary syndrome. J Atr Fibrillation. 2012;5(1):551. 11. KinjoK,SatoH,OhnishiY,HishidaE,NakataniD,MizunoH,etal.Prognostic significance of atrial fibrillation/atrial flutter in patients with acutemyocardial infarction treated with percutaneous coronary intervention. Am J Cardiol. 2003;92(10):1150-4. 12. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011;306(20):2248-54. 13. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESCGuidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. 14. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. 15. Lopes RD, Elliott LE, White HD, Hochman JS, Van deWerf F, Ardissino D, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30(16):2019-28. 16. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. 17. Gong X, Tang S, Li J, Zhang X, Tian X, Ma S. Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: a systematic review and network meta-analysis. PLoS One. 2017;12(10):e0186449. 18. Stenestrand U, Lindback J, Wallentin L, RIKS-HIA Registry. Anticoagulation therapy in atrial fibrillation in combinationwith acutemyocardial infarction influences long-termoutcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005;112(21):3225-31. 19. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525-30. 20. PedersonOD, Bagger H, Kober L, Torp-PedersenC. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100(4):376-80. 21. Danchin N, Fauchier L, Marijon E, Barnay C, Furber A, Mabo P, et al. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart. 2010;96(22):1809-14. 22. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926-33. References Author contributions Conception and design of the research, Analysis and interpretation of the data and Writing of the manuscript: Congo KH; Statistical analysis: Belo A; Critical revision of themanuscript for intellectual content: Belo A, Carvalho J, Neves D, Guerreiro R, Pais JA, Brás D, Carrington M, Piçarra B, Santos AR, Aguiar J. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Comissão Nacional Proteção de Dados under the protocol number 3140/2010. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 956